BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.480
-0.050 (-3.27%)
May 12, 2025, 4:00 PM - Market closed
BioXcel Therapeutics Employees
BioXcel Therapeutics had 37 employees as of December 31, 2024. The number of employees decreased by 37 or -50.00% compared to the previous year.
Employees
37
Change (1Y)
-37
Growth (1Y)
-50.00%
Revenue / Employee
$50,054
Profits / Employee
-$1,082,757
Market Cap
8.09M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BTAI News
- 1 day ago - BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Announces $14 Million Registered Direct Offering - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule - GlobeNewsWire